Carvedilol: a third-generation β-blocker should be a first-choice β-blocker

References

• Bristow MR, Ginsburg R, Umans V et al. β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ. Res.59, 297–309 (1986).
   PubMed Web of Science ®Google Scholar
• Packer M. Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET Trial. J. Card. Fail.9, 429–443 (2003).
   PubMed Web of Science ®Google Scholar
• Forster C, Armstrong PW. Pacing-induced heart failure in the dog: evaluation of peripheral vascular alpha-adrenoceptor subtypes. J. Cardiol. Pharmacol.16, 708–718 (1990).
   Google Scholar
• Hall JA, Kaumann AJ, Brown MJ. Selective beta 1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta 2-adrenoceptors in human atrial myocardium. Circ. Res.66, 1610–1623 (1990).
   PubMedGoogle Scholar
• Motomura S, Deighton NM, Zerkowski HR et al. Chronic beta 1-adrenoceptor antagonist treatment sensitizes beta 2-adrenoceptors, but desensitizes M2-muscarinic receptors in the human right atrium. Br. J. Pharmacol.101, 363–369 (1990).
   Google Scholar
• Xu XL, Zang WJ, Lu J et al. Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart. Auton. Neurosci.130, 6–16 (2006).
   Google Scholar
• Du XJ, Autelitano DJ, Dilley RJ et al. β2-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation101, 71–77 (2000).
   PubMed Web of Science ®Google Scholar
• Grupp IL, Lorenz JN, Walsh RA et al. Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absenceof hypertrophy. Am. J. Physiol.275, H1338–H1350 (1998).
   Google Scholar
• Kaddoura S, Firth JD, Boheler KR et al. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation93, 2068–2079 (1996).
   PubMed Web of Science ®Google Scholar
• Qin F, Rounds NK, Mao W et al. Antioxidant vitamins prevent cardiomyocyte apoptosis produced by norepinephrine infusion in ferrets. Cardiovasc. Res.51, 736–748 (2001).
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, Arleth AJ, Storer B et al. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J. Mol. Cell. Cardiol.30, 167–173 (1998).
   PubMedGoogle Scholar
• Houle MS, Altschuld RA, Billman GE. Enhanced in vivo and in vitro contractile responses to beta(2)-adrenergic receptor stimulation in dogs susceptible to lethal arrhythmias. J. Appl. Physiol.91, 1627–1637 (2001).
   PubMed Web of Science ®Google Scholar
• Lang CC, Rayos GH, Chomsky DB, Wood AJJ, Wilson JR. Effects of sympatho inhibition on exercise performance in heart failure. Circulation96, 238–245 (1997).
   PubMed Web of Science ®Google Scholar
• Kindermann M, Maack C, Schaller S et al. Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation109, 3182–3190 (2004).
   PubMed Web of Science ®Google Scholar
• Pini R, Cavallini MC, Palmieri V et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano study. J. Am. Coll. Cardiol.51, 2432–2439 (2008).
   PubMed Web of Science ®Google Scholar
• Polónia J, Barbosa L, Silva JA et al. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press. Monit.15(5), 235–239 (2010).
   PubMed Web of Science ®Google Scholar
• The CAFÉ Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation113, 1213–1225 (2006).
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J. Am. Coll. Cardiol.54, 705–713 (2009).
   PubMed Web of Science ®Google Scholar
• Packer M, Antonopoulos GV, Berlin JA et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am. Heart J.141, 899–907 (2001).
   PubMed Web of Science ®Google Scholar
• The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA59, 539–544 (1998).
   Google Scholar
• Cleland JG, Charlesworth A, Lubsen J et al. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality in patients with heart failure; a report from the Carvedilol or Metoprolol European Trial (COMET). J. Am. Coll. Cardiol.47, 1603–1611 (2006).
   Google Scholar
• Remme WJ, Cleland JG, Erhardt L et al. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. Eur. J. Heart Fail.9, 1128–1135 (2007).
   PubMed Web of Science ®Google Scholar
• Martsevich SY, Kutishenko NP, Deev AD et al. Comparison of antihypertensive and metabolic effects of carvedilol and metoprolol in hypertensive patients with overweight and obesity. J. Hypertens.28, e560 (2010).
   Google Scholar
• Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann. Intern. Med.126, 955–959 (1997).
   PubMed Web of Science ®Google Scholar
• Gilbert EM, Abraham WT, Olsen S. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation94, 2817–2825 (1996).
   PubMed Web of Science ®Google Scholar
• Morimoto S, Shimizu K, Yamada K et al. Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy? Am. Heart J.138, 456–459 (1999).
   PubMed Web of Science ®Google Scholar
• Lang CC, Rayos GH, Chomsky DB, Wood, AJJ, Wilson JR. Effects of sympatho inhibition on exercise performance in heart failure. Circulation96, 238–245 (1997).
   PubMed Web of Science ®Google Scholar
• Marfella R, Ziniscalchi M, Nappo F et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertnesive patients. Am. J. Hypertens.18, 308–318 (2005).
   PubMed Web of Science ®Google Scholar
• Hauf-Zachariou U, Wildmann L, Zulsdorf B et al. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur. J. Clin. Pharmacol.45, 95–100 (1993).
   PubMed Web of Science ®Google Scholar
• Fonseca VA. Effect of β-blockers on glucose and lipid metabolism. Curr. Med. Res. Opin.26, 615–629 (2010).
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J. Am. Coll. Cardiol.54, 705–713 (2009).
   PubMed Web of Science ®Google Scholar
• Frishman W, Henderson L, Lukas MA. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. Vasc. Health Risk Manag.4, 1387–1400 (2008).
   PubMedGoogle Scholar
• McGill JB, Bakris GL, Fonseca V et al. Beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes. Obes. Metab.9, 408–417 (2007).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Peacock WF, McMullin N et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure. An ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J. Am. Coll. Cardiol.52, 534–540 (2008).
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Welsh P, Lowe GD et al. N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without preexisting cardiovascular disease. J. Am. Coll. Cardiol.58, 56–64 (2011).
   PubMed Web of Science ®Google Scholar
• Chirinos JA, Zambrano JP, Chakko S et al. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension45, 980–985 (2005).
   PubMed Web of Science ®Google Scholar
• de Peuter OR, Lussan F, Peters RJG et al. A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth. J. Med.67, 284–294 (2009).
   Google Scholar
• Carlberb B, Samuelsson O, Lindholm LH et al. Atenolol in hypertension: is it a wise choice? Lancet364, 1684–1689 (2004).
   PubMed Web of Science ®Google Scholar
• Aurnes I, Osnes JB, Tvete IF, Gasemyr J Natvig B. Does atenolol differ from other β-adrenergic blockers? BMC Clin. Pharmacol.7, 4 (2007).
   PubMedGoogle Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet366, 1545–1553 (2005).
   PubMed Web of Science ®Google Scholar
• McAllister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Ann. Intern. Med.150(11), 784–794 (2009).
   Google Scholar
• Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation106, 2194–2199 (2002).
   PubMed Web of Science ®Google Scholar
• Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet357, 1385–1390 (2001).
   PubMed Web of Science ®Google Scholar
• Lopressor Intervention Trial Research Group. Multicentre study of metoprolol in survivors of acute myocardial infarction. Eur. Heart J.8, 1056–1064 (1987).
   PubMed Web of Science ®Google Scholar
• Jonsson G, Abdelnoor M, Muller C et al. A comparison of the two β-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction: a single-centre, randomized study of 232 patients. Cardiology103, 148–155 (2005).
   PubMed Web of Science ®Google Scholar
• Jonsson G, Abdelnoor M, Muller C et al. Effects of carvedilol compared to atenolol on ejection fraction and clinical endpoints after myocardial infarction. Eur. Heart J.24, 555 (2003) (Abstract P2892).
   Google Scholar
• Jonsson G, Abdelnoor M, Muller C et al. Effects of carvedilol compared to atenolol on ejection fraction and clinical endpoints after myocardial infarction. J. Am. Coll. Cardiol.43(Suppl. A), 289A (2004) (Abstract 1118–1177).
   Google Scholar
• Shen X, Nair CK, Aronow WS et al. Effect of carvedilol versus metoprolol CR/XL on mortality in patients with heart failure treated with cardiac resynchronization therapy: a COX multivariate regression analysis. Am. J. Ther. doi:10.1097/MJT.0b013e3181f2abb3 (2011) (Epub ahead of print).
   Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet362, 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Lopressor Intervention Trial Research Group. Multicentre study of metoprolol in survivors of acute myocardial infarction. Eur. Heart J.8, 1056–1064 (1987).
   PubMed Web of Science ®Google Scholar
• ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet2, 57–66 (1986).
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Herlitz J, Holmberg S et al. The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation67, I26–I32 (1983).
   PubMed Web of Science ®Google Scholar
• MIAMI Trial Research Group. Metoprolol in Acute Myocardial Infarction (MIAMI). A randomized placebo-controlled international trial. Eur. Heart. J.6, 199–226 (1985).
   PubMed Web of Science ®Google Scholar
• Roberts R, Rogers WJ, Mueller HS et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study. Circulation83, 422–437 (1991).
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Metra M, Charlesworth A et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure; data from the Carvedilol Or Metoprolol European Trial (COMET). Heart93, 968–973 (2007).
   PubMed Web of Science ®Google Scholar
• COMMIT collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised, placebo-controlled trial. Lancet366, 1622–1632 (2005).
   PubMed Web of Science ®Google Scholar
• Acikel S, Bozbas H, Gultekin B et al. Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. Int. J. Cardiol.135, 393–396 (2009).
   PubMed Web of Science ®Google Scholar
• Khamoushi AJ, Emkanjoo Z, Fazelifar AF et al. Optimal β-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. Heart Rhythm4, 1140–1174 (2007).
   Google Scholar
• No authors listed. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet353, 2001–2007 (1999).
   PubMed Web of Science ®Google Scholar
• Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet349, 375–380 (1997).
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med.334, 1349–1355 (1996).
   PubMed Web of Science ®Google Scholar
• CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation90, 1765–1773 (1994).
   PubMed Web of Science ®Google Scholar
• No authors listed. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet353, 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Willenheimer R, van Veldhuisen DJ, Silke B et al.; on behalf of the CIBIS III investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation112, 2426–2435 (2005).
   PubMed Web of Science ®Google Scholar
• Willenheimer R, Silke B. Possible clinical implications of the Cardiac Insufficiency Bisoprolol (CIBIS) III trial. Br. J. Cardiol.12, 448–454 (2005).
   Google Scholar
• Willenheimer R. The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial. Eur. Heart J.11, A15–A20 (2009).
   Google Scholar
• Flather MD, Shibata MC, Coats AJ et al.; on behalf of SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J.26, 215–225 (2005).
   PubMed Web of Science ®Google Scholar
• Tolg R, Witt M, Schwarz B et al. Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention – the PASSAT study. Clin. Res. Cardiol.95, 31–41 (2006).
   PubMed Web of Science ®Google Scholar
• Basu S, Senior R, Raval U, Van Der Does R, Bruckner T, Lahiri A. Benefical effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo controlled randomized trial. Circulation96, 183–191 (1997).
   PubMed Web of Science ®Google Scholar